Neurotransmitter Switching Coupled to β-Adrenergic Signaling in Sympathetic Neurons in Prehypertensive States

Emma N. Bardsley, Harvey Davis, Keith J. Buckler, David J. Paterson

Abstract—Single or combinatorial administration of β-blockers is a mainstay treatment strategy for conditions caused by sympathetic overactivity. Conventional wisdom suggests that the main beneficial effect of β-blockers includes resensitization and restoration of β1-adrenergic signaling pathways in the myocardium, improvements in cardiomyocyte contractility, and reversal of ventricular sensitization. However, emerging evidence indicates that another beneficial effect of β-blockers in disease may reside in sympathetic neurons. We investigated whether β-adrenoceptors are present on postganglionic sympathetic neurons and facilitate neurotransmission in a feed-forward manner. Using a combination of immunocytochemistry, RNA sequencing, Förster resonance energy transfer, and intracellular Ca2+ imaging, we demonstrate the presence of β-adrenoceptors on presynaptic sympathetic neurons in both human and rat stellate ganglia. In diseased neurons from the prehypertensive rat, there was enhanced β-adrenoceptor–mediated signaling predominantly via β1-adrenoceptor activation. Moreover, in human and rat neurons, we identified the presence of the epinephrine-synthesizing enzyme PNMT (phenylethanolamine-N-methyltransferase). Using high-pressure liquid chromatography with electrochemical detection, we measured greater epinephrine content and evoked release from the prehypertensive rat cardiac-stellate ganglia. We conclude that neurotransmitter switching resulting in enhanced epinephrine release, may provide presynaptic positive feedback on β-adrenoceptors to promote further release, that leads to greater postsynaptic excitability in disease, before increases in arterial blood pressure. Targeting neuronal β-adrenoceptor downstream signaling could provide therapeutic opportunity to minimize end-organ damage caused by sympathetic overactivity. (Hypertension. 2018;71:1226-1238. DOI: 10.1161/HYPERTENSIONAHA.118.10844.) • Online Data Supplement

Key Words: cardiovascular diseases ▪ epinephrine ▪ hypertension ▪ sequence analysis, RNA ▪ stellate ganglion

The myocardial β-adrenergic receptor (βAR) signaling pathway plays a pivotal role in the pathogenesis of many cardiovascular diseases. Chronic cardiac adrenergic activation and impaired myocardial cyclic nucleotide (cN) signaling, resulting from enhanced catecholaminergic neurotransmission, are well-established contributors to ventricular hypertrophy, arrhythmia, and cardiomyocyte apoptosis.1–3 Sympathetic overactivity and vagal impairment (dysautonomia) are recurrent features in normotensive subjects with a familial predisposition for hypertension4 and in animal models of this disease.5–8 Moreover, patients with familial dysautonomia experience catecholaminergic supersensitivity, episodic hypertension, and have a high propensity for fatal cardiac events.9 β-Blockers are a mainstay treatment for many cardiovascular diseases and stress-related events.10 Chronic β-blocker therapy affords patients a wide-range of beneficial effects, including β1,AR resensitization and restoration of intracellular cN signaling pathways, improvements in cardiac myocyte contractility, and reversal of ventricular remodeling.1,3 The precise mechanisms, however, that mediate and sustain the beneficial effects of β-blockers in disease remain unclear,11,12 although the presence of potentiating Gαo-coupled presynaptic βARs on presynaptic sympathetic terminals suggests a role for β-blockers in regulating cardioneuronal communication.13–22 The Adrenaline Hypothesis of hypertension argues that small incremental increases in plasma adrenaline (epinephrine) enhance sympathetic activity through sustained activation of presynaptic sympathetic βARs, leading to the development of hypertension.23,24 Whether epinephrine synthesis occurs before the onset of hypertension is not known, as there is limited cellular and molecular data within the sympathetic stellate ganglia to confirm this idea.

In this study, we investigated whether sympathetic βARs are present on human and rat sympathetic stellate ganglia (cervicothoracic ganglia, T1–T3) that preferentially innervate the heart.25–28 We aimed to establish whether intracellular second messenger signaling coupled to presynaptic βARs is impaired in prehypertensive states and contributes to altered Ca2+ and cN signaling before increases in arterial blood pressure. Finally,
we aimed to assess which neurotransmitters are present within the cardiac-sympathetic ganglia to test the idea that epinephrine may act as the preferential sympathetic neurotransmitter, predisposing to disease.

**Methods**

**Data Accessibility**

Our RNA sequencing (RNAseq) raw FastQ files are deposited in the National Center for Biotechnology Information short reads archive under Short Reads Archive number SRP132271, and our quasi-mapped data will be available under Gene Expression Omnibus accession number (GSE110197).

**Clinical Samples**

For clinical samples, human stellate ganglia were kindly sent by Drs Ajjjola, Ardell, and Shivkumar from University of California, Los Angeles, Cardiac Arrhythmia Center. Characteristics of human donors are included in the online-only Data Supplement (Table S1 in the online-only Data Supplement). The human study was approved by the University of California, Los Angeles, Institutional Review Board (approval no. 12-000701), and informed consent was obtained from all subjects.

**Animals**

Young male prehypertensive spontaneously hypertensive rats (pre-SHRs) of 3.5 to 5.5 week old, 16- to 20-week-old adult male normotensive Wistar rats, and age-matched spontaneously hypertensive rats (SHRs) were obtained from Envigo, United Kingdom. The SHR strain displays normal blood pressure at 4 weeks of age, where increases in arterial blood pressure develop progressively from 5 to 6 weeks of age. In this study, we used the Wistar rat strain as the normotensive control, given that Wistar rats are the progenitor strain from which the Wistar Kyoto was bred and the 2 strains display similar hemodynamic profiles at all ages. In addition, neither strain display a sympathetic Ca²⁺ phenotype (Figure S1A), making the Wistar a suitable control in this study. All rats were housed in standard plastic cages, and artificial lighting was fixed to a natural 12-hour light/dark cycle. Food and water were available ad libitum. All experiments were performed in accordance with the UK Home Office Animal Scientific Procedures Act 1986 and approved by the University of Oxford (PPL 30/3131; David J. Paterson). An expanded Materials and Methods section is available in the online-only Data Supplement for neuronal culture methodology, immunocytochemistry, RNAseq, Förster resonance energy transfer (FRET), Ca²⁺ imaging, and high-pressure liquid chromatography coupled to electrochemical detection protocols.

**Results**

**Rat and Human Sympathetic Stellate Ganglia Express β₁ and β₂ Adrenoceptors**

We sequenced the transcriptome of the sympathetic stellate ganglia from 16-week-old male Wistar rats (n=4) and SHR (n=4). At 16 weeks, it is well-established that SHR display hypertension and sympathetic hyperactivity. Using quasi-mapping RNAseq and quantitative real-time (qRT)-polymerase chain reaction (PCR), we identified the presence of β₁ AR (Adrb1) and β₂ AR (Adrb2) mRNA transcripts, in addition to α₁A AR (Adra2a) and tyrosine hydroxylase (Th) mRNA transcripts, markers of presynaptic sympathetic neurons, respectively (Figure 1A; Figure S1). We selected the α₂CAR isoform as an indicator of presynaptic neuronal phenotype based on reports that the α₂CAR primarily regulates presynaptic sympathetic activity. The α₂CAR isoform plays a secondary role in regulating presynaptic norepinephrine release, whereas the α₁AR isoform has a preferential role within the vasculature.

The mRNA expression for α₁AR was also found to be significantly higher than α₁AR expression identified by RNAseq (data not shown). Using RNAseq, we found that Adrb2 mRNA expression was significantly lower in SHR ganglia compared with Wistar (Figure 1A; Figure S1C; P.adj=0.00945). Data points represent mean raw counts±SEM. The presence of Adrb1, Adrb2, Adra2a, and Th mRNA transcripts was identified and quantified by quantitative real-time PCR (qRT-PCR) using RNA extracted from 4-week pre-SHR and Wistar rats (n=3 rats/group, unpooled; Figure S1D) and 16-week SHR and Wistar rats (n=4 rats/group, unpooled; Figure S1D). qRT-PCR data were analyzed using the ΔΔCT method, where raw counts in both strains were first normalized to a control housekeeping gene B2m, and the difference in counts between SHR and Wistar was calculated.

Data points represent log₂ (fold change)±SEM. There was no significant difference in the levels of mRNA for Adrb1, Adrb2, Adra2a, or Th between strains or between age groups by qRT-PCR although the trend for a reduction in Adrb2 expression remained.

Sandwich ELISAs were used to quantify the relative protein expression of β₁AR and β₂ARs in postganglionic sympathetic neurons obtained from 3- to 5-week-old normotensive pre-SHR and Wistar rats (Figure 1B; 32 stellates, 16 rats/group, pooled) or 19- to 20-week-old SHR and age-matched Wistar rats (Figure 1C; 20 stellates, 10 rats/group, pooled). The ELISA assays were biologically powered where 20 to 32 stellates were used per sample; however, the stellates tissue was pooled to obtain an adequate protein concentration for the ELISA assays, therefore no statistical comparisons were made. Data points indicate mean±SEM (of 3–4 technical replicates).

In 4 stellate ganglia samples obtained from 3 human donors (2 left stellates, 2 right stellates, unpooled), qRT-PCR confirmed the presence of mRNA transcripts encoding β₁AR (Adrb1) and β₂AR (Adrb2; S1E). Ganglia were α₁AR (Adra2a) positive, confirming a presynaptic phenotype. Samples were normalized to a control housekeeping gene B2m (3 replicates) using the ΔCT method. Using normalized counts±SEM, ELISAs confirmed the expression of β₁AR (516±99.17 pg/mL) and β₂AR (340±104.3 pg/mL) in 3 human stellates obtained from 2 patients (Figure 1D; pooled, 6 replicates). Immunocytochemistry confirmed the expression of β₁AR and β₂AR on TH-positive neurons from 3- to 5-week-old control rats (Figure 1E and 1F; respectively) and SHR (data not shown).

**βAR-Evoked cAMP Generation, PKA Activity, and [Ca²⁺]ᵢ Are Enhanced in Pre-SHR Neurons**

To determine whether the presence of presynaptic βARs on sympathetic ganglia plays a functional role in modulating intracellular cN signaling pathways, we used FRET to quantify the relative levels of cAMP and PKA (protein kinase A) activity in response to a relatively nonselective βAR agonist, isoprenaline. To assess whether βAR-mediated cAMP generation facilitated signaling via the canonical cAMP–PKA–Ca²⁺ pathway, we used the loss-of-FRET sensor Epacs1-H187 (EpacH187) to measure changes in intracellular cAMP. Isoprenaline administration at 10 nmol/L led to significantly greater cAMP generation in pre-SHR (55.6%±16.8%)
compared with that measured in Wistar neurons (7.1%±1.4%; 2-way ANOVA; P<0.0001) that was also observed at higher concentrations of isoprenaline (Figure 2A and 2B). PKA activity was measured using the gain-of-FRET sensor AKAR4. Using the same concentration of isoprenaline (10 nmol/L), we found that PKA activity was significantly higher in pre-SHR (26.1%±5.4%) versus Wistar neurons (4.5%±1.1%; 2-way ANOVA; P<0.0001), which was also observed at 100 nmol/L isoprenaline (Figure 2C and 2D). Raw YFP (yellow fluorescent protein) and CFP (cyan fluorescent protein) fluorescence traces as emitted from the cytosolic loss-of-FRET sensor EpacH187 and the gain-of-FRET sensor AKAR4 in

Figure 1. Rat sympathetic stellate ganglia express β₁- and β₂-adrenergic receptors (ARs). Using RNA sequencing, we identified the presence of β₁AR (Adrb1), β₂AR (Adrb2), and α₂AAR (Adra2a) mRNA transcripts (A) from 16-wk-old male Wistar rats (n=4) and SHR (n=4). Adrb2 expression was significantly lower in SHR ganglia compared with Wistar (P.adj=0.00945; Salmon-DESeq2 method). There was no significant difference in the levels of mRNA for Adrb1 or Adra2a between strains or between age groups. Data points represent raw counts±SEM for each transcript (A). ELISAs confirmed protein expression of β₁AR and β₂ARs in 3.5- to 5-wk-old rat neurons (32 stellates, 16 animals/group) and 20-wk-old neurons (20 stellates, 10 animals/group); however, no statistical tests were conducted as stellates were pooled into a single sample to obtain adequate protein concentrations for the ELISA assays. In young rat stellates (B), the concentration of β₁AR protein was calculated as 869.1±50.6 pg/mL (Wistar) and 114.2±23.7 pg/mL (pre-SHR). β₁AR protein expression was calculated as 869.1±50.6 pg/mL (Wistar) and 114.2±23.7 pg/mL (pre-SHR). β₁AR protein expression was calculated as 363.5±43.6 pg/mL (Wistar) and 82.2±20.0 pg/mL (pre-SHR). In adult rat stellates (C), β₁AR protein expression was calculated as 674.1±44.6 pg/mL (Wistar) and 489.4±26.3 pg/mL (SHR). β₁AR protein expression quantified as 353.3±11.2 pg/mL (Wistar) and 147.4±20.7 pg/mL (SHR). Data points depict mean±SEM of 3 to 4 technical replicates. β₂AR (516±99.17 pg/mL) and β₂AR (340±104.3 pg/mL) expression was also detected in stellate ganglia from human donors. Data points represent mean±SEM (6 replicates), from 3 pooled stellates obtained from 2 patients (D). Immunocytochemistry depicts β₁AR (E) and β₂AR (F) expression on TH (tyrosine hydroxylase)-positive neurons from 4-wk control rats. White arrows demonstrate the localization of β₂AR on synaptic terminals.
response to isoprenaline (10–100 nmol/L) are presented in the online-only Data Supplement (Figure S2A and S2B).

To assess whether isoprenaline-dependent βAR activation enhances intracellular Ca²⁺ ([Ca²⁺]i), we measured responses to KCl in the absence or presence of isoprenaline. Ca²⁺ recordings were obtained using Indo-1AM labeled sympathetic neurons from 4-week pre-SHR and Wistar rats. In pre-SHR stellate neurons, KCl stimulation in the presence of isoprenaline led to significantly higher [Ca²⁺]i than KCl stimulations alone (Figure 2E and 2F; P=0.0272). There was significantly higher KCl-evoked [Ca²⁺]i in the presence of isoprenaline in pre-SHR neurons compared with that recorded in control neurons (Figure 2E and 2F; P=0.0027). A time-controlled example trace is shown in the online-only Data Supplement (Figure S2C).

Relative Contribution of β1AR and β2AR Signaling in Neuronal cAMP Generation

To ascertain whether the observed increases in isoprenaline-evoked cAMP occurs predominantly through either β₁AR or β₂AR activation, cells were challenged with either a β₁AR agonist (dobutamine, 50 μmol/L) after β₁AR blockade with ICI-118,551 (ICI, 10 nmol/L) or in alternative experiments, administration of a β₂AR agonist (salbutamol, 10 μmol/L) after β₂AR antagonism (metoprolol, 100 nmol/L). Administration of the β₁AR agonist dobutamine led to significantly greater cAMP generation in pre-SHR (15.82%±2.8%) compared with Wistar neurons (−0.31%±2.4%; 2-way ANOVA; P<0.0001; Figure 3A and 3C). We observed that in Wistar neurons, administration of dobutamine did not increase cAMP from baseline. Administration of the β₂AR agonist salbutamol also led to a significantly greater cAMP generation in pre-SHR (63.8%±16.6%) compared with Wistar neurons (38.6%±5.2%; 2-way ANOVA; P<0.0001; Figure 3B and 3C). There was significantly higher peak salbutamol-evoked cAMP compared with dobutamine-evoked cAMP in Wistar (P<0.0001; Mann–Whitney) and in pre-SHR neurons (P=0.0173, unpaired 2-tailed Student t test), highlighting a greater contribution of β₁AR versus β₂AR in generating cAMP, regardless of strain (C).
To confirm that isoprenaline-evoked cAMP is acting through β₁AR and β₂ARs rather than inducing off-target effects, we tested isoprenaline-evoked cAMP in the absence and presence of a combination of β₁AR agonist, dobutamine (DOB, 50 μmol/L) after β₁AR inhibition with a selective antagonist, ICI-118,551 (ICI, 10 nmol/L) that led to a significantly greater increase in cAMP generation in pre-SHR (15.82%±2.8%; n=5) compared with Wistar neurons (−0.31%±2.4%; n=10; 2-way ANOVA; P<0.0001). In Wistar neurons, administration of DOB did not increase cAMP from baseline (A). In alternative experiments, neurons were stimulated with a β₂AR agonist salbutamol (SAL, 10 μmol/L) after β₂AR inhibition with a selective antagonist, metoprolol (MET, 100 nmol/L). SAL administration led to a greater increase in cAMP generation in pre-SHR (63.8%±16.6%; n=12) compared with Wistar neurons (38.6%±5.2%; n=13; 2-way ANOVA; P<0.0001; B). Peak FRET ratios (%) evoked by DOB or SAL were calculated (C). SAL generated significantly higher cAMP levels, than that evoked by DOB in Wistar (P<0.0001, Mann–Whitney) and in pre-SHR PGSNs (P=0.0173, unpaired 2-tailed Student t test). To confirm that ISO-evoked cAMP was acting downstream of βAR activation, we tested ISO-evoked cAMP in the absence and presence of a combination of β₁AR and β₂AR antagonists (ISO, 10 μmol/L; MET, 10 μmol/L; ICI, 1 μmol/L, respectively) or selective blockade of either β₁AR (MET, 10 μmol/L) or β₂AR (ICI, 10 nmol/L). The dual combination of β-blockers abolished cAMP generation in both pre-SHR (n=6) and Wistar neurons (n=6), demonstrating that ISO-dependent cAMP generation is dependent on βAR activation (D). There was significantly greater inhibition of cAMP after β₂AR compared with β₁AR inhibition in Wistar (P<0.0001; 2-way repeated measures ANOVA) and pre-SHR neurons (P<0.0001; 2-way repeated measures ANOVA), suggesting that β₂AR plays a predominant role in cAMP generation, regardless of strain (E). Peak FRET responses are depicted (F).
β1AR and β2AR activation (Figure 3D). To support these observations, we also selectively inhibited β1AR (metoprolol, 10 μmol/L) or β2AR (ICI, 10 nmol/L) and measured the resulting cAMP generation in response to isoprenaline (10 μmol/L). β1AR blockade reduced isoprenaline-evoked cAMP generation to a greater extent than β2AR blockade in both Wistar and pre-SHR neurons, confirming our previous observations for a preferential effect of β2AR versus β1AR mediated signaling in postganglionic sympathetic neurons (Figure 3E and 3F). We measured a slight but significantly greater cAMP generation in pre-SHR versus Wistar neurons in the presence of either metoprolol (P=0.0472).
or ICI (P<0.001) using 2-way repeated measure ANOVAs; however, the peak FRET responses themselves were not different significantly between strains (Figure 3F). The selectivity and specificity of the selected β1AR and β2AR agonists (dobutamine and salbutamol, respectively) and the β1AR and β2AR antagonists (metoprolol and ICI) have been previously reported.46–51

Epinephrine-Synthesizing Enzyme PNMT Is Present in Rat and Human Stellate Ganglia

RNAseq was performed to obtain an overview of the transcriptome in stellate ganglia obtained from 16-week-old male SHR (n=4) and Wistar rats (n=4). We identified the presence of mRNA transcripts-encoding enzymes required for norepinephrine synthesis (Figure 4A): phenylethanolamine hydroxylase (Pah), Th, L-DOPA decarboxylase (Ddc), dopamine β-hydroxylase (Dbh). Furthermore, RNAseq identified the presence of the mRNA transcript encoding phenylethanolamine-N-methyltransferase (Pnmt), the enzyme required for the conversion of norepinephrine to epinephrine in both Wistar and SHR stellate ganglia. In the RNAseq data set, Pah and Ddc mRNA transcript expression were also shown to be significantly lower in SHR neurons (Figure 4B; Figure S3A; P.adj=0.0719; 6.64×10⁻¹⁵, Pah, Ddc, respectively). These findings were validated in 4-week Wistar and pre-SHR by qRT-PCR, and a significant 4-fold reduction in Pah expression was observed in pre-SHR ganglia (Figure 4C; P=0.0098). Data were normalized to a control housekeeping gene (B2m) and SHR gene counts were subsequently normalized to Wistar using the ΔΔCt method. Data were presented as Log₂(fold change).45 Using the same method, we also confirmed the presence of Pnmt and Th by qRT-PCR in neurons from 16-week Wistar and SHR (Figure S3B). There was no significant difference in mRNA expression of either Th or Pnmt between age groups or between phenotypes. ELISA assays confirmed protein expression of TH (Figure 4D) and PNMT (Figure 4E) in stellate ganglia from 4-week pre-SHR, 20-week-old SHR, and age-matched Wistar rats. The ELISA assays were high-powered biologically, where 20 to 32 stellates were used per sample; however, stellates were pooled to obtain adequate protein concentrations for the ELISA assays, therefore no statistical comparisons were made. Data points indicate mean±SEM (of 2–3 technical replicates).

To assess whether the presence of PNMT in sympathetic stellate ganglia is conserved in higher species, we obtained stellate ganglia from male human donors. qRT-PCR demonstrated the presence of both Th and Pnmt mRNA transcripts in human sympathetic stellate ganglia (Figure S3C). Data were normalized to a control housekeeping gene B2m using the ΔΔCt method46 and expressed as normalized count values (3 patients, 4 stellates). We also used ELISAs to confirm protein expression of both TH and PNMT in human stellate samples (Figure 4F). Data points represent mean±SEM (2–3 replicates) from 3 pooled stellates obtained from 2 patients.

Epinephrine Is Released From Pre-SHR but Not Wistar Whole-Stellate Ganglia

After the identification of PNMT, we investigated whether epinephrine is released from the whole rat stellate ganglia under basal conditions or with electric field stimulation. We measured significantly greater total norepinephrine content in homogenized Wistar stellates (43.3±2.173 pg; n=8) compared with pre-SHR stellate ganglia (29.82±6.366 pg; n=4; P=0.0294). In the same homogenate, we measured a greater content of epinephrine in pre-SHR ganglia (14.14±5.399 pg) compared with that measured in Wistar stellates (3.937±0.820 pg; P=0.0019), suggesting that a significant amount of norepinephrine is converted to epinephrine in prehypertensive states (Figure 5A).

We also investigated whether epinephrine is released from rat stellate ganglia with electric stimulation (Figure 5B). Electrically evoked concentrations of norepinephrine were significantly higher in samples obtained from pre-SHR (4.32±1.523 pg; n=4) versus Wistar ganglia (1.477±0.316 pg; n=8; P=0.0396). Moreover, in the same samples, the concentrations of electrically evoked epinephrine were significantly higher in pre-SHR (4.424±1.391 pg; n=4) compared with Wistar stellates (0.3201±0.0325 pg; n=8; P=0.0028).
higher in pre-SHR ganglia (4.424±1.391 pg) compared with that measured in Wistar stellates (0.3201±0.0325 pg; P=0.0396).

Discussion
In this study, we have obtained evidence for β1AR and β2AR mRNA and protein expression on presynaptic postganglionic sympathetic neurons from human and rat ganglia. We have further demonstrated that in isolated sympathetic neurons, βAR agonists elevate cAMP and activate PKA. The effects were more pronounced in neurons from pre-SHR rats. We also observed that βAR agonists enhanced [Ca2+]i in response to depolarization by high K+ in pre-SHR neurons only. In addition, we demonstrate the presence of mRNA and protein expression of PNMT, the enzyme involved in the synthesis of epinephrine in human and rat sympathetic stellate neurons. Moreover, we observed that epinephrine is present in diseased states and is actively released from prehypertensive, but not healthy rat neurons, suggesting preferential switching of neurotransmitter synthesis in disease.

Single or combinational administration of β-blockers is a mainstay treatment strategy for diseases caused by sympathetic overactivity, although the precise mechanisms that underpin the long-term beneficial effects are not entirely clear. Current dogma suggests that the observed antihypertensive and cardioprotective effects of β-blockers are mediated through inhibition of cardiac and vascular βARs, reducing myocardial work and total peripheral resistance. Our findings suggest that the efficacy of clinical β-blockers may be attributed, at least in part, to a reduction in sympathetic hyperactivity and neurotransmission at the end-organ.

What is the cause for increased sympathetic neurotransmission before the onset of neurogenic hypertension? Emerging evidence suggests that impaired nitric oxide synthesis and reductions in cGMP–PKG (protein kinase G) signaling lead to pathological increases in [Ca2+]i, and norepinephrine release at the end-organ. Recently, we demonstrated that increased cGMP signaling leads to enhanced N-type Ca2+ channel (Cα2.2) currents and that this effect may be ameliorated by artificially increasing cytosolic cGMP. Additional evidence suggests that impaired nitric oxide synthesis and reductions in cGMP–PKG signaling lead to pathological increases in [Ca2+]i, and norepinephrine release at the end-organ.

To assess whether βAR signaling facilitates cardiac-sympathetic neurotransmission, [Ca2+]i was measured in response to KCl in the absence or presence of isoprenaline. Consistent with the observed increases in βAR-mediated cAMP–PKA signaling in pre-SHR neurons, isoprenaline also increased KCl-evoked [Ca2+]i in prehypertensive states; whereas there was no effect of isoprenaline in control neurons (Figure 2E and 2F). These data demonstrate that enhanced βAR-mediated signaling in sympathetic neurons contributes to the Ca2+ phenotype and increases sympathetic transmission. Previous work has demonstrated that the N-type calcium channel is the primary voltage-gated channel responsible for Ca2+ influx in sympathetic neurons and carries a significantly larger Ca2+ current in pre-SHR and SHR neurons compared with controls.

To establish whether the observed increases in cAMP–PKA activity occur downstream of β1AR or β2AR signaling, cells were perfused with selective agonists for either β1AR or β2AR subtypes in the presence of either alternate βAR antagonist. We found that selective activation of β1AR or β2AR led to significantly greater increases in cAMP in pre-SHR neurons compared with Wistar. Indeed, there was no measureable effect of β1AR activation on [cAMP] in normotensive controls (Figure 3). Furthermore, stimulation of pre-SHR neurons with the β2AR agonist salbutamol led to cAMP generation that was almost twice as high as β1AR-evoked cAMP within pre-SHR neurons, suggesting a dominant role for β2AR compared with β1AR signaling. To establish whether increased βAR signaling in pre-SHR results from increases in βAR expression, we measured levels of β1AR and β2AR mRNA via qRT-PCR and RNAseq and quantified protein levels using sandwich ELISAs. Surprisingly, we observed that βAR transcripts and protein expression are reduced in pre-SHR stellates, as well as in aged SHR with established hypertension. Compared with age-matched Wistar neurons, in a similar manner to that reported in the myocardium. We also report that in healthy ganglia, β2AR expression decreases with age, much like in the heart (Figure 1). Together, these data suggest that in diseased states, the potentiating effects of βAR agonists may be mediated through impaired second messengers coupled to cAMP and its effector PKA, probably via impairment of phosphodiesterases to hydrolyze cAMP rather than the G-protein coupled receptors themselves.

Which neurotransmitter preferentially activates presynaptic βARs? Several studies suggest limited involvement of norepinephrine in potentiating presynaptic neurotransmission but argue for a critical role for epinephrine in enhancing release, particularly in patients with essential hypertension or stress disorders. The role of epinephrine in the pathogenesis of essential hypertension has been termed the Adrenaline Hypothesis; however, the origins of local concentration of epinephrine remain unclear. Most reports suggest that high circulating plasma epinephrine concentrations...
arise from the adrenal medulla with active reuptake into sympathetic nerve terminals. Others have identified heightened epinephrine synthesis within the central nervous system, specifically the nucleus tractus solitarius and hypothalamus, and suggest that this source of epinephrine may underpin the high plasma levels of epinephrine. Alternatively, some reports have identified in situ epinephrine synthesis within various sympathetic ganglia in rat and human, via a stress-inducible mechanism. Our identification of PNMT mRNA and protein expression in human and rat cardiac-sympathetic ganglia (Figure 4) supports the findings of these earlier studies that epinephrine is synthesized in sympathetic stellate ganglia in disease.

What is the relevance of epinephrine synthesis in pre-hypertensive sympathetic stellate ganglia? The Adrenaline Hypothesis of hypertension proposes that stress and subsequent small incremental increases in epinephrine plays a major role in the pathogenesis of hypertension, not via epinephrine directly, but as a result of increased sympathetic activity and enhanced norepinephrine release. This sustained increase in sympathetic activity caused by epinephrine leads to the development of hypertension. We have shown that epinephrine is synthesized in pre-SHR to a greater extent than in healthy sympathetic stellate ganglia and is only released from pre-SHR ganglia. Importantly, epinephrine has a 10-fold higher affinity for β₂AR than norepinephrine (EC₅₀ 5.2, 53.7 nmol/L, respectively) and is capable of generating 3x more cAMP than norepinephrine via β₂AR activation, a feature that may be mimicked by isoprorenaline because of similarities in efficacy. Subsequently, the high efficacy of epinephrine (and the relatively low efficacy of norepinephrine) at β₂AR has been shown to result in epinephrine-dependent norepinephrine transmission. Indeed, low concentrations of epinephrine (0.1–10 nmol/L) have been shown to be 100x to 500x more potent than norepinephrine in enhancing activity-dependent norepinephrine release. Moreover, epinephrine may have a more sustained effect on norepinephrine release because of the extended tissue half-life of epinephrine. Epinephrine-induced norepinephrine release has been identified in a wide variety of peripheral tissues in rat, rabbit, and human.

We sought to investigate whether the presence of pre-synaptic PNMT plays a functional role in converting norepinephrine to epinephrine in rat stellate ganglia, by measuring total catecholamine content and electrically evoked catecholamines by high-pressure liquid chromatography coupled to electrochemical detection (Figure 5). We identified a significant decrease in total norepinephrine content in pre-SHR ganglia (74.8% of total catecholamine content) compared with norepinephrine calculated in Wistar ganglia (91.5% of total catecholamine content). We have also observed that the total content of epinephrine was significantly higher in pre-SHR ganglia (25.2% of total catecholamine content) compared with epinephrine levels quantified in Wistar ganglia (8.5% of total catecholamines measured). Furthermore, we found that on electric stimulation, the percentage ratio of norepinephrine:epinephrine released from Wistar ganglia was calculated as 91%-9%; whereas in pre-SHR ganglia, the ratio of catecholamines released (norepinephrine:epinephrine) was 44%:56% (Figure 5), although the total amounts of catecholamines released during electric stimulation remained fairly similar between the strains (=11–12 pg).

One recurrent feature in human and animal models of hypertension is the reduction in norepinephrine reuptake transport (NET), leading to larger and more sustained extracellular catecholamine concentrations. Recently, it has been proposed that PNMT may also act as a DNA methylase, silencing NET transcription that may underpin the observed NET phenotype. We have previously identified reductions in NET activity in the pre-SHR cardiac-stellate ganglia.

Limitations

In this study, we investigated the role and mechanisms involved in feed-forward presynaptic signaling in the cardiac-sympathetic ganglia. We performed a hypothesis neutral, nonbiased approach to sequencing the transcriptome of sympathetic stellate in adult rats that revealed the presence of RNA transcripts involved βAR receptor expression and epinephrine synthesis. We assessed the functional relevance of these findings by probing the adrenergic intracellular signaling pathways coupled to Ca²⁺-mediated exocytosis. There were several limitations to these approaches. First, the stellate ganglion comprises a heterogeneous population of cell types. Indeed, we identified markers of fibroblasts and astrocytes, including vimentin and glial fibrillary acidic protein, respectively; however, we identified that a high number of transcripts were neuronal in phenotype. We also found that the subunit profile of nicotinic acetylcholine receptors matches those described for sympathetic neurons. Moreover, immunocytochemistry highlighted the localization of β- and α1ARs on the soma and dendrites of TH-positive neurons. In support of these data, our collaborators have also identified the presence of transcripts encoding presynaptic βARs in sorted sympathetic mouse neurons (Ana Domingos, personal communication, 2018). Second, in the absence of cardiac tracing experiments, we rely on anatomic literature, and our own previous observations that the results presented here are relevant to cardiac-sympathetic communication because significant myocardial sympathetic innervation has been shown to arise from the cervicothoracic ganglia. Third, we used stellates obtained from male rats. Although sex differences in hypertension and cardiovascular disease incidence have been widely reported, in this study, we focused on investigating the transcriptome of the male rat stellate ganglia given that the prevalence for cardiovascular diseases is significantly higher in males than premenopausal women. Fourth, cNs and phosphodiesterases reside in distinct subcellular compartments, and their localization with βAR receptors is acutely regulated. Similarly, the regulation of Ca²⁺ channels by PKA/PKG occurs in distinct signalosomes, conferring site-specific regulation of Ca²⁺ entry coupled to neurotransmission. Furthermore, the rate of phosphodiesterase hydrolysis is critically dependent on the concentration of both cAMP and cGMP that is reported to be different between cell types. In this study, we measured global
cytosolic cAMP, PKA, and Ca\(^{2+}\) concentrations, therefore we cannot ascertain precisely where the key pathways converge. Site-specific FRET and Ca\(^{2+}\) sensors will be required to resolve the question of microdomain impairments in eN and effector signaling.

**Perspectives**

Our data here demonstrate that in prehypertensive and hypertensive states, epinephrine is synthesized within presynaptic sympathetic nerve terminals and released on activation at the end-organ. In prehypertensive states, evoked release of epinephrine (that is exacerbated by decreased NET activity) may act preferentially on presynaptic β\(_2\)ARs to increase cAMP generation and PKA activity, thereby enhancing Ca\(^{2+}\) levels and neurotransmission in disease, in a manner akin to positive feedback. We suggest that epinephrine release at the end-organ may play a role in the pathogenesis of hypertension. Figure 6 depicts the model signaling pathways in healthy and prehypertensive states and highlights potential sites for neural phenotypic targeting in disease. We suggest that in a model of early hypertension, activation of presynaptic βARs enhances cAMP generation, PKA activity, and [Ca\(^{2+}\)]\(_i\) to greater levels than that measured in healthy neurons, facilitating neurotransmission in a potentiating feed-forward manner. This occurs preferentially via β\(_2\)AR activation. Catecholamines may also be supplied from the circulation. We propose that β-blockers may have efficacy at βARs expressed on peripheral neurons, by reducing cardiac-sympathetic communication in hypertension and dysautonomias. ACh indicates acetylcholine; and nAChRs, nicotinic acetylcholine receptors.

---

**Figure 6.** Model figure. The sympathetic stellate ganglia (cervicothoracic ganglia) are located alongside vertebrate T1 to T3. They are the primary sympathetic ganglia that innervate the heart and have been shown to exert the greatest control over increases in heart rate and contractility.\(^{25-28}\) In healthy postganglionic sympathetic neurons (A), Ca\(^{2+}\)-dependent exocytosis facilitates the release of norepinephrine (NE) onto cardiac myocytes, where postsynaptic β\(_1\)- and β\(_2\)-adrenergic receptors (ARs) are activated. Increases in extracellular NE acts on presynaptic α\(_2\)ARs, reducing adenylyl cyclase (AC) activity through activation of inhibitory G\(_i\) G-proteins. Acute regulation of cAMP is maintained by phosphodiesterases (PDEs).\(^{90,91}\) cAMP-dependent PKA (protein kinase A) activity increases intracellular Ca\(^{2+}\) ([Ca\(^{2+}\)]\(_i\)) via phosphorylation of the N-type Ca\(^{2+}\) Channel ([Ca\(^{2+}\); CaV2.2])\(^{55}\); regulation of endoplasmic reticulum stores and mitochondrial Ca\(^{2+}\) release.\(^{31}\) In neurons obtained from the prehypertensive SHR, a young genetic model of hypertension (B), Ca\(^{2+}\)-dependent exocytosis facilitates the release of NE and epinephrine (Epi). Activation of presynaptic βARs in prehypertensive states\(^{29-36}\) enhances cAMP generation, PKA activity, and [Ca\(^{2+}\)]\(_i\) to greater levels than in healthy neurons, facilitating neurotransmission in a potentiating feed-forward manner. This occurs preferentially via β\(_1\)AR activation. Catecholamines may also be supplied from the circulation. We propose that β-blockers may have efficacy at βARs expressed on peripheral neurons, by reducing cardiac-sympathetic communication in hypertension and dysautonomias.
renin–angiotensin–aldosterone release, chronic inflammatory diseases, and heart failure.

Acknowledgments

We acknowledge the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z) for the generation of the sequencing data. We acknowledge our collaborators Drs Ajjijola, Shivkumar, and Ardell at the University of California, Los Angeles, Cardiac Arhythmia Center for kindly extracting and shipping human sympathetic stellate ganglia from donor patients no. 19, no. 23, and no. 24. We thank Dr Threlfell in our department for her help and expertise with high-pressure liquid chromatography coupled to electrochemical detection experimental design and protocols. E.N. Bardsley and D.J. Paterson planned the project. E.N. Bardsley performed all of the rat and human RNA extraction, validation, and quantitative real-time polymerase chain reaction experiments. E.N. Bardsley performed all cell culturing and performed Ca2+ imaging, Förster resonance energy transfer imaging, ELISAs, and immunocytochemistry. K.J. Buckler assisted with the Ca2+ experiments. H. Davis performed the catecholamine high-pressure liquid chromatography coupled to electrochemical detection experiments. E.N. Bardsley analyzed all experimental data. E.N. Bardsley and H. Davis performed the RNA sequencing differential expression analysis. E.N. Bardsley and D.J. Paterson cowrote the paper. All authors edited the manuscript.

Sources of Funding

This project was funded by the Wellcome Trust OXION initiative (105409/Z/14/Z), British Heart Foundation (BHF) Centre of Research Excellence and BHF (RG1/17/14/33085), and National Institutes of Health SPARC (OT20D023848) initiative.

Disclosures

None.

References

1. Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014;114:1815–1826. doi: 10.1161/CIRCRESAHA.114.302589.
2. Sprenger JU, Perera RK, Steinhuber JH, Lehmann SE, Maier LS, Hasenfuss G, Nikolaevo V. In vivo model with targeted cAMP biosensor reveals changes in receptor-microdomain communication in cardiac disease. Nat Commun. 2015;6:6965. doi: 10.1038/ncomms7965.
3. Najafi A, Sequeira V, Kuster DW, van der Velden I. β-adrenergic receptor signalling and its functional consequences in the diseased heart. Eur J Clin Invest. 2016;46:362–374. doi: 10.1111/eci.12598.
4. Piccirillo G, Viola E, Nocco M, Durante M, Marigliano V. Human sympathetic nerve biology: parallel influences of stress and epigenetics in essential hypertension and panic disorder. Ann NY Acad Sci. 2008;114:1815–1826. doi: 10.1161/CIRCRESAHA.114.302589.
5. Ely DL, Friberg P, Misu Y, Kubo T. Presynaptic beta-adrenoceptors. Med Res Rev. 2016;6:197–225.
6. Marrazzi AS. Electrical studies on the pharmacology of autonomic synapses ii. The action of a sympathomimetic drug (epinephrine) on sympathetic ganglia. J Pharmacol Exp Ther. 2006;35:395–404.
7. Goodall M, Kirshner N. Biosynthesis of epinephrine and norepinephrine by sympathetic nerves through activation of ACTH receptors, β-adrenoceptors and angiotensin II receptors. Br J Pharmacol. 1988;95:993–1001.
8. Majewski H. Review modulation of noradrenaline release through activation of pre- and postsynaptic beta-receptors in the cardiovascular system. Ann NY Acad Sci. 1990;604:528–544.
9. Apparsundaram S, Eikendugan DC. Role of prejunctional beta adrenoceptors in rat cardiac sympathetic neurotransmission. Br J Pharmacol. 1995;117:519–526.
10. Costa M, Majewski H. Facilitation of noradrenaline release from sympathetic nerves through activation of ACTH receptors, β-adrenoceptors and angiotensin II receptors. Br J Pharmacol. 1998;95:1001–1003.
11. Misu Y. Kubo T. Presynaptic beta-adrenoceptors. Med Res Rev. 2016;6:197–225.
12. Wysonge CS, Bradley HA, Volmink J, Mayosi BM. Cochrane corner: beta-blockers for hypertension. Heart. 2018;104:282–283. doi: 10.1136/heartjnl-2017-311585.
13. Adler-Grashinsky E, Langer SZ. Possible role of a beta-adrenoceptor in the regulation of noradrenaline release by nerve stimulation through a possible feedback mechanism. Br J Pharmacol. 1975;53:43–50.
14. Nedergaard OA, Abrahamsen J. Modulation of noradrenaline release by activation of presynaptic beta-adrenoceptors in the cardiovascular system. Am J Physiol Heart Circ Physiol. 1983:155–155. doi: 10.1152/ajpheart.1983.245.2.528.
15. Lokhandwala MF, Eikendugan DC. Presynaptic receptors and alterations in norepinephrine release in spontaneously hypertensive rats. Life Sci. 1983;33:1527–1542.
16. Misu Y, Kubo T. Presynaptic beta-adrenoceptors. Med Res Rev. 2016;6:197–225.
17. Majewski H. Review modulation of noradrenaline release through activation of presynaptic beta-adrenoceptors. J Auton Pharmacol. 1983;3:155–155. doi: 10.1111/1474-8663.1983.1800592.x.
18. Lokhandwala MF, Eikendugan DC. Presynaptic receptors and alterations in norepinephrine release in spontaneously hypertensive rats. Life Sci. 1983;33:1527–1542.
19. Kawashima T. The autonomic nervous system of the human heart with special reference to its origin, course, and peripheral distribution. Anat Embryol. 2005;209:425–438. doi: 10.1007/s00429-005-0462-1.
20. Korzina MB, Korbkin AA, Vasiliev OA, Maslyukov PM. Morphological characteristics of the stellate ganglia in white rats. Neurosci Behav Physiol. 2011;41:436–439. doi: 10.1007/s11055-011-9433-6.
21. Ellison JP, Williams TH. Sympathetic nerve pathways to the human heart, and their variations. Am J Anat. 1969;124:149–162. doi: 10.1002/aja.1001240203.
22. Yogesh M, Zhou W, Shi J, Ajjijola OA, Hadaya J, Shivkumar K, Mahajan A. Sympathetic innervation of the anterior left ventricular wall by the right and left stellate ganglia. Heart Rhythm. 2012;9:1303–1309. doi: 10.1016/j.hrthm.2012.03.052.
23. Judy WV, Watanabe AM, Murphy WR, Aprison BS, Yu PL. Sympathetic nerve activity and blood pressure in normotensive backcross rats genetically related to the spontaneously hypertensive rat. Hypertension. 1979;1:598–604.
24. Dickhout JG, Lee RM. Blood pressure and heart rate development in young spontaneously hypertensive rats. Am J Physiol. 1998;274(3 pt 2):H794–H800.
25. Li D, Lee CW, Buckler K, Parekh A, Hering N, Paterson DJ. Abnormal intracellular calcium homeostasis in sympathetic neurons from young prehypertensive rats. Hypertension. 2012;59:642–649. doi: 10.1161/HYPERTENSIONAHA.111.184640.
26. Shanks J, Manou-Stathopoulou S, Lu CJ, Li D, Paterson DJ, Herring N. Cardiac sympathetic dysfunction in the prehypertensive spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2013;305:H980–H986. doi: 10.1152/ajpheart.00255.2013.
27. Heijnen BF, Van Essen H, Schalkwijk CG, Janssen BJ, Struijk-Jongerden HA. Renal inflammatory markers during the onset of hypertension in young spontaneously hypertensive rats. Hypertension. 2018;104:282–283. doi: 10.1161/HEARTJNL-2017-311585.
28. Komolova M, Friberg P, Adams MA. Altered vascular resistance properties and acute pressure-natriuresis mechanism in neonatal and weaning spontaneously hypertensive rats. Hypertension. 2012;59:979–984. doi: 10.1161/HYPERTENSIONAHA.111.178194.
29. Ely DL, Friberg P, Nilsson H, Folkow B. Blood pressure and heart rate responses to mental stress in spontaneously hypertensive rats (SHR) and
normotensive (WKY) rats on various sodium diets. Acta Physiol Scand. 1985;123:159–169. doi: 10.1111/j.1476-1656.1985.tb07573.x.

36. Wilson AJ, Wang YV, Sands GB, Young AA, Nash MP, LeGrice IJ. Increased cardiac work provides a link between systemic hypertension and heart failure. Physiol Rep. 2017;5:e13104. doi: 10.14814/phy2.13104.

37. Paduano W, McBryde FD, Marvar PJ, Lincevicus GS, Abdala AP, Woodward L, Li D, Paterson DJ, Paton JF. Carotid sinus denervation ameliorates renovascular hypertension in adult Wistar rats. J Physiol. 2016;594:6255–6266. doi: 10.1113/JP272708.

38. Oliveira-Sales EB, Colombari E, Abdala AP, Campos RR, Paton JF. Sympathetic overactivity occurs before hypertension in the two-kidney, one-clip model. Exp Physiol. 2016;101:67–80. doi: 10.1113/EP085390.

39. Oliveira-Sales EB, Toward MA, Campos RR, Paton JF. Revealing the role of the autonomic nervous system in the development and maintenance of Goldblatt hypertension in rats. Auton Neurosci. 2014;183:23–29. doi: 10.1016/j.autneu.2014.02.001.

40. Abdala AP, McBryde FD, Marina N, Hendy EB, Engelmann ZJ, Fudim M, Sobotta PA, Gourein AV, Paton JF. Hypertension is critically dependent on the carotid body input in the spontaneously hypertensive rat. J Physiol. 2012;590:4269–4277. doi: 10.1113/jphysiol.2012.237800.

41. Smith TL, Hutchins PM. Central hemodynamics in the developmental stage of spontaneous hypertension in the unanesthetized rat. Hypertension. 1979;1:508–517.

42. Lee RM. Structural alterations of blood vessels in hypertensive rats. Can J Physiol Pharmacol. 1983;61:528–534.

43. Composa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, Szczech JA, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, Szczech JA. The selectivity of beta-adrenoceptor antagonists at the human beta-adrenergic receptor stimulant. J Cardiovasc Pharmacol. 2009;53:181–184.

44. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3:1100–1108. doi: 10.1038/nprot.2008.73.

45. Klarenbeek J, Goedhart J, van der Zwan CA, Veenstra DN, Zibilovcakova L, Micutkova L, Bartosova Z, Sabban EL, Krizanova O, Vatrova VI, Coppes RP, Dahlöf C, Zaagsma J. Pre- and postganglionic neurons. Front Physiol. 2015;6:120. doi: 10.3389/fphys.2015.00120.

46. Wu H, Liu J, Zhang D, Zheng H, Patel KP, Cornish KG, Wang WZ, Muelleman RL, Li YL. Heart failure-induced changes of voltage-gated Ca2+ channels and cell excitability in rat cardiac postganglionic neurons. Am J Physiol Cell Physiol. 2014;306:C132–C142. doi: 10.1152/ajpcell.00223.2013.

47. Blumenthal SJ, McConnaughey MM, Iams SG. Myocardial adrenergic receptors and adenylyl cyclase in the developing spontaneously hypertensive rat. Clin Exp Pharmacol Physiol. 1982;9:483–486.

48. Madamanchi A. Beta-adrenergic receptor signaling in cardiac function and heart failure. Mamm Gen Med. 2007;10:99–104.

49. Rumantir MS, Jennings GL, Lambert GW, Kaye DM, Seals DR, Esler MD. The ‘adrenaline hypothesis’ of hypertension revisited: evidence for adrenaline release from the heart of patients with essential hypertension. J Hypertens. 2000;18:717–723.

50. Wilson DM, Thompson LM, Lambert GW, Jennings GL, Schwarz RG, Jefferys D, Turner AG, Esler MD. Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psychiatry. 1998;55:511–520.

51. Alvarenga ME, Richards JC, Lambert G, Esler MD. Psychophysiological mechanisms in panic disorder: a correlative analysis of noradrenaline spillover, neuronal noradrenaline reuptake, power spectral analysis of heart rate variability, and psychological variables. Psychosom Med. 2006;68:8–16. doi: 10.1097/PSY.0b013e318309f782.00987.db.

52. Majewska H, Hedler L, Starke K. The noradrenaline release rate in the anaesthetized rabbit: facilitation by adrenaline. Naunyn Schmiedebers Arch Pharmacol. 1982;321:20–27. doi: 10.1007/BF00586343.

53. Caramona MM, Soares-da-Silva P. The effects of chemical sympathome- tomy on dopamine, noradrenaline and adrenaline content in some periph- eral tissues. Br J Pharmacol. 1978;65:1703–1711.

54. Munch G, Nguyen NTB, Nekolla S, Ziegler S, Muzik O, Chakraborty P, Wieland DM, Schwaiger M. Evaluation of sympathetic nerve terminals with [11C]epinephrine and [11C]hydroxyephedrine and positron emission tomography. Circulation. 2000;101:516–523. doi: 10.1161/01.CIR.101.5.516.

55. Gianutsos G, Moore KE. Epinephrine contents of sympathetic ganglia and brain regions of spontaneously hypertensive rats of different ages. Proc Soc Exp Biol Med. 1978;158:45–49.

56. Torda C. Hypothalamic adrenaline synthesis after stimulation of the medial forebrain bundle. Br J Pharmacol. 1977;61:5–8.

57. Kennedy B, Elayan H, Ziegler MG. Lung epinephrine synthesis. Am J Physiol. 1990;258(4 pt 1):L227–L231. doi: 10.1152/ajplung.1990.258.4.L227.

58. Kubovcakova L, Micutkova L, Bartosova Z, Sabbah EL, Krizanova O, Vatrova VI, Coppes RP, Dahlöf C, Zaagsma J. Pre- and postganglionic neurons. Front Physiol. 2006;97:1419–1430. doi: 10.1111/j.1471-4159.2006.03832.x.

59. Zeman M, Petrák J, Stebéková N, Nagy G, Krizanova O, Herichová I, Kvetnanský R. Endocrine rhythms and expression of selected genes in the brain, stellate ganglia, and adrenals of hypertensive TGR rats. Physiol Res. 2016;65:1419–1430. doi: 10.1111/j.1471-4159.2016.03832.x.

60. Kazanietz MG, Enero MA. Role of cyclic AMP in the release of noradrenaline from isolated rat atria. Effect of pretreatment with clenbuterol. Naunyn Schmiedebers Arch Pharmacol. 1992;345:367–374.

61. Remie R, Knop HT, Bos EA, Zaagsma J. Characterization of presynaptic beta-adrenoceptors facilitating endogenous noradrenaline release in the portal vein of permanently cannulated, freely moving rats. Eur J Pharmacol. 1988;157:37–43.

62. Majewska H, Murphy TV. Beta-adrenoceptor blockade and sympathetic neurotransmission in the pituitary in rats. J Hypertens. 1989;7:991–996.

63. Kazanietz MG, Enero MA. Modulation of noradrenaline release by presynaptic alpha-2 and beta adrenoceptors in rat atria. Effect of pre- treatment with clenbuterol. Naunyn Schmiedebers Arch Pharmacol. 1989;340:274–278.

64. Tarizzo VI, Coppes RP, Dahlöf C, Zaagsma J. Pre- and postganglionic stimulation-induced noradrenaline overflow is markedly facilitated by a prejunctional beta 2-adrenoceptor-mediated control mechanism in the pituitary. Naunyn Schmiedebers Arch Pharmacol. 1994;349:570–577.

65. Brg T. β1-blockers lower norepinephrine release by inhibiting presynaptic, facilitating β1-adrenoceptors in normotensive and hypertensive rats. Front Neurol. 2014;5:51. doi: 10.3389/fneur.2014.00051.

66. Brg T. Altered β1-3-adrenoceptor influence on α2-adrenoceptor-mediated control of catecholamine release and vascular tension in hyper- tensive rats. Front Physiol. 2015;6:120. doi: 10.3389/fphys.2015.00120.

67. Tu H, Liu J, Zhang D, Zheng H, Patel KP, Cornish KG, Wang WZ, Muelleman RL, Li YL. Heart failure-induced changes of voltage-gated Ca2+ channels and cell excitability in rat cardiac postgangli- conic neurons. Am J Physiol Cell Physiol. 2014;306:C132–C142. doi: 10.1152/ajpcell.00223.2013.
Hypertension  June 2018

What Is New?

- We provide evidence for β1- and β2-adrenergic receptors in human stellate ganglia. These receptors are also conserved in rat stellate. We demonstrate that the cAMP–PKA signaling pathway coupled to activation of β2-adrenergic receptors is impaired and exacerbates the Ca2+ phenotype in young prehypertensive rats.
- We have also shown that prehypertensive rat stellate neurons synthesize and release epinephrine.

What Is Relevant?

- Neurotransmitter switching to epinephrine may be an early cellular marker because this neurochemical phenotype may reflect sympathetic impairment in the early stages of disease progression.
- Targeting the β2-adrenergic intracellular signaling pathway and reducing PNMT (phenylethanolamine-N-methyltransferase) activity may be therapeutically relevant for the early treatment of sympathetic dysautonomia.

Summary

Using a combination of RNA sequencing, quantitative real-time polymerase chain reaction, immunocytochemistry, ELISA, Förster resonance energy transfer and Ca2+ imaging, we have shown the presence β2-adrenergic receptors on presynaptic sympathetic neurons in human and rat. We have demonstrated that catecholaminergic stimulation of these receptors exacerbates the sympathetic Ca2+ phenotype in the pre-SHR before the onset of hypertension. Using high-pressure liquid chromatography coupled to chemical detection, we have also found that physiological concentrations of epinephrine are released from sympathetic ganglia before increases in blood pressure occur. This may reflect a site of neural impairment in disease progression.
Neurotransmitter Switching Coupled to β-Adrenergic Signaling in Sympathetic Neurons in Prehypertensive States
Emma N. Bardsley, Harvey Davis, Keith J. Buckler and David J. Paterson

Hypertension. 2018;71:1226-1238; originally published online April 23, 2018; doi: 10.1161/HYPERTENSIONAHA.118.10844

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/71/6/1226
Free via Open Access

Data Supplement (unedited) at:
http://hyper.ahajournals.org/content/suppl/2018/04/20/HYPERTENSIONAHA.118.10844.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/
ONLINE SUPPLEMENT

NEUROTRANSMITTER SWITCHING COUPLED TO BETA-ADRENERGIC SIGNALING IN SYMPATHETIC NEURONS IN PREHYPERTENSIVE STATES

Emma N. Bardsley*¹, Harvey Davis¹, Keith J. Buckler¹, David J. Paterson*¹
¹Wellcome Trust OXION Initiative in Ion Channels and Disease, Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics, Sherrington Building, University of Oxford, Oxford, OX1 3PT, UK

*Corresponding Authors: Miss Emma Nicole Bardsley, University of Oxford, Department of Physiology, Anatomy and Genetics, Oxford, OX1 3PT, UK; emma.bardsley@dpag.ox.ac.uk, tel. +44 (0)1865 272471.
Prof. David James Paterson, University of Oxford, Department of Physiology, Anatomy and Genetics, Oxford, OX1 3PT, UK; david.paterson@dpag.ox.ac.uk, tel. +44 (0)1865 272471.

Short title: Neurotransmitter Switch in Prehypertension
Supplemental Materials and Methods

**Reagents.** All drugs and reagents were sourced from Sigma-Aldrich UK unless otherwise stated.

**Adenovirus generation.** The cAMP-sensitive FRET sensor Epacs1-H187 (EpachH187) and the PKA-sensitive FRET sensor AKAR4 were obtained as described previously\(^1\). Generation and amplification of the virus particles was outsourced to Vector Biolabs.

**Neuronal Isolation from Rat Sympathetic Cardiac Ganglia.** Rats were anaesthetized in an induction chamber (3-5% isoflurane) and humanely killed by a Home Office approved Schedule 1 method: overdose of pentobarbital (Euthatal, 200 mg/mL) and exsanguination. The stellate ganglia were removed, de-sheathed from connective tissue, dissected and enzymatically digested with collagenase (type IV, 1 mg/mL, 37 °C) and trypsin (type I, 1 mg/mL, 37 °C). Stellates were washed with a modified L-15 blocking medium that was equilibrated prior to use (37 °C, 5 % CO\(_2\)) and the ganglia were dissociated into a single-cell suspension via manual trituration in pre-equilibrated plating medium (37 °C, 5 % CO\(_2\)). Post-ganglionic sympathetic neurons (PGSNs) were plated on Poly-D-Lysine/laminin-coated coverslips (6 mm, VWR International) and incubated in plating medium (37 °C, 5 % CO\(_2\)) until required for use.

**Immunocytochemistry.** PGSNs were cultured from 3-5-week pre-SHR and Wistar control rats. Stellate neurons were fixed with paraformaldehyde (2%, 5 mins) before blocking and permeabilizing with goat serum (10%), bovine serum albumin (0.3%) and Triton X-100 (0.1%) in dPBS without Ca\(^{2+}\) and Mg\(^{2+}\) (1-hour, room temperature (RT)). Cells were washed thoroughly with dPBS (3 x 10 min) and incubated in primary antibodies (1-hour, 37 °C). The following antibodies were used: anti-tyrosine hydroxylase (TH, 1:250, T1299, Abcam), anti-\(\beta_1\)AR (ab3442, 1:100, Abcam), anti-\(\beta_2\)AR, (ab182136, 1:200, Abcam). Cells were incubated with the appropriate secondary antibodies (Alexa Fluor, 1:1000, 2 hours, 37 °C) before they were mounted on microscope slides using medium containing DAPI (Vectashield, Vector Laboratories) and sealed. Control experiments that were carried out in the absence of primary antibodies did not display any fluorescence except DAPI, confirming the absence of non-specific binding. Specificity of primary antibodies for \(\beta_1\)AR and \(\beta_2\)AR was also validated via Western blotting (data not shown). Cells were imaged using 40X or 60X objectives on a confocal microscope (Live Cell Olympus Inverted Confocal or Zeiss LSM 880 Airy Scan Upright Confocal). Z-stack images were edited and cell sizes were measured using Fiji software (ImageJ)\(^2,3\).

**RNA Extraction from Sympathetic Cardiac Ganglia for RNA Sequencing and qRT-PCR.** Left and right PGSNs were dissected from 16-week-old male SHR and age-matched male Wistar rats. Briefly, rats were anaesthetized in an induction chamber (3-5% isoflurane) and humanely killed by a Home Office approved Schedule 1 method: overdose of pentobarbital (Euthatal, 200 mg/mL) and exsanguination. Right stellate ganglia were removed for RNA sequencing and the left stellate ganglia were used for matched qRT-PCR experiments. Stellate ganglia were placed in Hanks Buffered Saline Solution without Ca\(^{2+}\) and Mg\(^{2+}\). For clinical samples, human stellate ganglia were kindly sent by Drs Ajijola, Ardell and Shivkumar.
Online Supplement: Neurotransmitter Switch in Prehypertension

from UCLA Cardiac Arrhythmia Center and shipped on dry ice in RNaLater® RNA Stabilization Solution (ThermoFisher). Rat and human ganglia were cleaned and de-sheathed. Each ganglion was transferred immediately to RLT lysis buffer (Qiagen) with β-mercaptoethanol (1%), and each sample contained tissue from one stellate. Rat stellates were finely chopped and carefully triturated with fire-blown Pasteur pipettes until adequately digested. Human stellates were manually homogenized. RNA was extracted using an RNeasy Mini RNA Extraction Kit (Qiagen) and human RNA was extracted using an RNeasy Maxi RNA Extraction Kit (Qiagen) in accordance with the manufacturer’s instructions. RNA samples were aliquoted for qRT PCR and quality control experiments, snap frozen in liquid nitrogen and stored at -80 °C. The RNA quality and integrity from each sample, was confirmed using a 2100 Bioanalyzer Instrument with an RNA picochip (Agilent). Rat samples with an RNA Integrity Number (RIN) less than 8.5 were discarded. Due to difficulties with fast shipping of human samples we accepted human RNA samples with RINs above 5.7. RNA concentrations were determined using a Qubit RNA High Sensitivity Assay Kit (Molecular Probes, Life Technologies) and a Qubit® 2.0 Fluorometer (Invitrogen, Life Technologies).

cDNA library preparation for RNA Sequencing. Four replicate samples containing total RNA extracted from the right sympathetic stellate ganglion of 16-week-old male SHR (n=4) and age-matched Wistar (n=4) were sent to the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics (WTCHG) for RNAseq library construction and sequencing using an Illumina HiSeq 4000 (Illumina, Inc., San Diego, USA). The sequencing libraries were amplified using a SMARTer (first strand synthesis) amplification protocol due to the low initial RNA concentrations obtained from a single stellate and prepared for paired-end sequencing (2 x 75 bp). Each sample was sequenced on two separate lanes to minimize technical error and to increase the sequencing depth (~15-25 million reads per lane). Samples were randomized and blinded to the experimenter. The number of replicates and the sequencing parameters established, were based on recommendations from WTCHG and those published by Conesa et al., 20162.

Quasi-mapping. Transcripts were quantified via the Salmon (version 0.8.2) package using the transcriptome-based quasi-mapping mode3. The following commands were used for quasi-mapping in accordance with the Salmon guidelines:
salmon quant I transcripts_index -I ISR a -1 /SampleX_lane1_mate1.fastq.gz / SampleX_lane2_mate1.fastq.gz -2 / SampleX_lane1_mate2.fastq.gz / SampleX_lane2_mate2.fastq.gz -o Sample1 --dumpEq --posBias --gcBias –writeUnmappedNames. The transcript index used during quasi-mapping was derived from the UCSC refseq rn6.0 mRNA library available at the following link: http://hgdownload.soe.ucsc.edu/goldenPath/rn6/bigZips/refMrna.fa.gz. Data files were assigned alternative names to blind the experimenter during the relevant stages of the quasi-mapping analysis.

RNAseq Differential Expression Analysis. Following sample quantification, the data were imported into R and summarized at the gene-level using the ‘Tximport’ function (v1.4.0)4. A differential expression analysis of the gene counts for Wistar and SHR samples was performed using the ‘DESeq2’ command in the R package DESeq2 (version 1.16.1)4. Significance for differential expression was accepted at the Benjamini-Hochberg adjusted
value p<0.05. The ‘LFCshrink’ function was used to shrink log$_2$ fold change after analysis, for visualization and ranking of genes, as per the DESeq2 vignette.

**cDNA Library Preparation for qRT-PCR.** 50 ng stellate RNA was obtained for constructing qRT-PCR cDNA libraries (n=4/group). For conversion of rat PGSN RNA, the SuperScript™ III VILO™ cDNA synthesis protocol was followed according to manufacturer’s instructions. For conversion of human PGSN RNA, the SuperScript™ IV VILO™ cDNA synthesis protocol was followed according to manufacturer’s instructions (ThermoFisher). The concentration of cDNA in each sample and the 260/280 ratios were calculated (NanoDrop Lite) to detect the presence of contaminants. cDNA samples with an abnormal 260/280 ratio (<1.7 and >1.95) were discarded. The cDNA samples were aliquoted and numerically labelled to blind the experimenter to the rat strain during experimentation. Samples were frozen at -80 °C for long-term storage or retained at 4 °C for immediate use.

**Two-Step Quantitative Real-Time Polymerase Chain Reaction.** qRT-PCR was used to confirm the presence of the following mRNA transcripts in the PGSN cDNA libraries: β$_1$AR (Adrb1; Rn00824536_s1, Hs002330048_s1; rat, human respectively), β$_2$AR (Adrb2; Rn00560650_s1, Hs00240532_s1; rat, human), α$_2$αAR (Adra2a; Rn00562488_s1, Hs01099503_s1); PAH (Pah; Rn00561708_m1, rat), TH (Th; Rn00562500_m1, Hs01002182_m1; rat, human), DDC (Ddc; Rn00561708_m1, rat), DBH (Dbh; Rn00565819_m1, rat), PNMT (Pnmt; Rn01495589_g1, Hs01557113_g1; rat, human respectively). The following controls were selected: beta-2-microglobulin (B2m; Rn00560865_m1, Hs00187842_m1; rat, human), glyceraldehyde-3-phosphate dehydrogenase (Gapdh; Rn00560865_s1, Hs02786624_g1; rat, human). TaqMan® Gene Expression Master Mix (ThermoFisher) was added to each cDNA sample in addition to the selected primer conjugated to a FAM dye and nuclease-free H$_2$O. cDNA samples or control samples with no reverse transcriptase were diluted 1:20 for optimal PCR reactions. 20 μL samples (3 repeats) were added to a 96-well plate and run on a real-time quantitative PCR thermocycler (ABI, PRISM). Temperatures were held at 50 °C (2 min) and 95 °C (10 min) before thermal cycling (40 cycles) under the following conditions 95 °C (15 s), 60 °C (1 min). Data displayed in the results section depicts gene counts normalised to B2m; however, each primer was analysed against two housekeeping genes, B2m and Gapdh for validation and accuracy of qRT-PCR data. The relative amount of each transcript was calculated using the comparative (C$_T$) method (ΔΔ C$_T$, rat; Δ C$_T$, human).

**Quantitative Enzyme Linked Immunosorbent Assay (ELISA).** Protein was extracted from stellate ganglia obtained from 4-week and 20-week male SHR, age-matched Wistar rats and human donors. 100 mg of rat stellate tissue was pooled and homogenized in ice-cold dPBS without Ca$^{2+}$ or Mg$^{2+}$. In alternative experiments, tissue from three human ganglia (80 mg) was separately homogenized in ice-cold dPBS without Ca$^{2+}$ or Mg$^{2+}$. The protein concentration in each sample was quantified using a protein assay (BioRad DC) as per manufacturer’s instructions and the total protein concentration in each sample was normalized. Protein concentrations were established using sandwich ELISAs for β$_1$AR (CSB-EL001391RA, CSB-EL001391HU; rat, human respectively), β$_2$AR (CSB-EL001392RA, CSB-EL001392HU; rat, human respectively), PNMT (CSB-EL018274RA, CSB-EL018274HU; PNMT rat, human respectively) and TH (CSB-EL018274RA, CSB-EL018274HU; PNMT rat, human respectively) and TH (CSB-EL018274RA, CSB-EL018274HU; PNMT rat, human respectively) and TH (CSB-EL018274RA, CSB-EL018274HU; PNMT rat, human respectively). ELISA assays were performed in accordance with the manufacturer’s instructions (CUSABIO,
USA). Background absorbance was measured at 540 nm and subtracted from the values obtained at 450 nm (Infinite F500, TECAN). Absolute concentrations of protein were quantified using a standard curve generated from the supplied standards.

**Live-Cell Förster Resonance Energy Transfer (FRET) Microscopy.** FRET was employed to monitor real-time changes in intracellular cAMP generation and protein kinase (PKA) activity in randomly selected PGSNs obtained from 4-week pre-SHR and Wistar rats. Stellate neurons were cultured and transduced with adenovirus particles encoding the respective FRET biosensors Epacs1H187: 5.1 x 10⁸ PFU / mL, AKAR4: 1.3 x 10⁹ PFU / mL) for 24 hours. Experiments were blinded wherever possible, however due to the comprehensive 3-4-day culturing/imaging protocol, it was not possible for a single experimenter to be blinded during the imaging experiments. To detect dynamic changes in cytosolic cAMP or PKA activity, cells were transduced with the loss-of-FRET sensor Epacs1H187 or the gain-of-FRET biosensor A Kinase Activity Reporter 4 (AKAR4) respectively. FRET biosensor-expressing neurons were imaged 3-4 days post-culture, on an inverted microscope (Nikon) connected to an OptoLED fluorescence imaging system (Cairn Research Ltd., UK). Cells were imaged using 40X or 60X oil-immersion objectives and images were captured with a CoolSNAP HQ2 digital CCD camera (Photometrics). A beam splitter (DV2 Photometrics) included the emission filters for CFP and YFP (ET480/30M, ET535/40M) respectively, and a dichroic mirror (505DCXR). The cells were excited at 430 nm for 100 ms every 15 s. CFP and YFP emission intensities were measured at 480 nm and 535 nm were acquired using Optofluor software (Cairn Research Ltd., UK). For the Epacs1H187 loss-of-FRET sensor, CFP / YFP ratios were calculated. For AKAR4, a gain-of-FRET sensor, YFP / CFP emission intensity ratios were calculated. Background fluorescence was subtracted from emission intensity ratios and data were expressed as intensity per unit time. Mean FRET responses were expressed as the percentage change from baseline (∆R/R₀ where ∆R = R - R₀. R₀ is the mean ratio over 30 s at baseline in the absence of drug, and R is the mean ratio calculated over 30 s in the presence of drug treatment).

During FRET experiments, cells were perfused continuously with Tyrode’s solution via a gravity-fed perfusion system and the flow rate was controlled at 2-3 ml/min. A stable baseline of at least 2 minutes was required at the start of each experiment. Pharmacological compounds were diluted in Tyrode solution and perfused at the following concentrations: isoprenaline (ISO) 10 nmol/L to 10 μmol/L; β₁AR agonist dobutamine (DOB) 50 μmol/L; β₁AR antagonist metoprolol, 100 nmol/L to 10 μmol/L; β₂AR agonist salbutamol (SAL), 10 μmol/L; β₂AR agonist ICI 118,551 10 nmol/L to 10 μmol/L. In all experiments, the maximal FRET change of each cell was recorded by exposing the cells to saturating concentrations of an adenylyl cyclase (AC) activator forskolin (FSK) 25 μmol/L and a non-specific PDE inhibitor 3-isobutyl 1-methylxanthine (IBMX) 100 μmol/L, to ensure that the cells responded similarly to the biosensors. In the absence of a FSK/IBMX response, cells were excluded from analysis. The number of cells per group were based on previously-calculated power analyses. For comparisons between cells, the average percentage FRET change was calculated over a 30 s period once equilibrium was established.

**Real-Time Calcium Measurements.** PGSNs from 4-week pre-SHR and Wistar rats were dissected, dissociated and incubated for 4-6 hours on the day of culture until they fully adhered to Poly-D-Lysine / laminin-coated coverslips (37°C, 5% CO₂). To investigate Ca²⁺
responses to ISO, neurons from 4-week Wistar and pre-SHR were incubated in Indo-1 acetoxyethyl ester (Indo-1AM, ThermoFisher; 2 μmol/L, 45 mins, RT). Stellate neurons loaded with Indo-1AM were imaged on an inverted Nikon Diaphot 200 microscope (Nikon, Tokyo, Japan) and excited at 340 nm with a 100 W Xenon lamp (Nikon, Tokyo, Japan). The emission was split by a dichroic mirror (450 nm) and fluorescence was detected at 405 nm (calcium bound) and 495 nm (calcium free) by two tri-alkali photomultiplier tubes (PMTs, ET Enterprises Ltd., UK) each housed in air cooled enclosures (FACT50, ET Enterprises Ltd., UK) to maintain PMT temperatures at -20 °C. The output from each PMT was integrated in a current-to-voltage converter and digitized at a sampling frequency of 250 Hz (CED 1401). Signals at 405 nm and 495 nm were acquired with Spike2 software and automatically converted into a ratio (495 nm / 405 nm). Recorded values were averaged over 0.5 s intervals providing a final sampling rate of 2 Hz.

During Ca\(^{2+}\) imaging experiments a stable baseline was recorded for 30 s prior to stimulation. PGSNs were subsequently stimulated with 50 mmol/L KCl in CO\(_2\)/HCO\(_3\) buffered Tyrode solution with an equimolar reduction in NaCl. Upon return to baseline, cells were perfused with isoprenaline (ISO, 1 μmol/L) for 4 minutes and re-stimulated with 50 mmol/L K\(^+\) in the presence of ISO (1 μmol/L). For control experiments, no ISO was administered. In the absence of a KCl response, cells were excluded from analysis. The values obtained from the Ca\(^{2+}\) peak following each KCl stimulation were averaged and baseline values were subtracted from absolute peak size. To determine the effect of the compound on KCl-evoked [Ca\(^{2+}\)]; the ratio ‘S2 / S1’ was calculated, where S2 was the stimulus in the presence of drug and S1 was the stimulus prior to drug administration. Ratios were compared to time-controlled experiments, where S1 and S2 were both recorded in the absence of drug. Ratiometric data were obtained through conversion of raw data sheets into text files. Fluorescence values were transformed to [Ca\(^{2+}\)] concentrations using the following equation derived by Grynkiewicz et al., \(^8\):

\[
[Ca^{2+}]_i = K_d \times \frac{sf}{sb} \times \left\{ \frac{R - R_{\text{min}}}{R_{\text{max}} - R} \right\}
\]

For control experiments measuring intracellular Ca\(^{2+}\), Wistar and WKY neurons were cultured and grown on Poly-D-lysine/laminin-coated coverslips (6 mm, VWR International) and incubated in plating medium (37 °C, 5 % CO\(_2\)) for 36-48 hours. Prior to imaging, cells were incubated in plating media with the ratiometric Ca\(^{2+}\) dye Fura-2AM (ThermoFisher; 2 μmol/L, 45 mins, RT). Calcium concentrations were measured at baseline (Tyrode’s, 37 °C) and in response to a KCl challenge (50 mmol/L, equimolar reduction in NaCl, 37 °C). Fura-2AM was excited at 340/380 nm at an interval of 3500 ms. The emitted fluorescence was calculated at 510 nm and converted to Ca\(^{2+}\) concentrations using the Grynkiewicz equation as described\(^8\).

**High-Pressure Liquid Chromatography Coupled to Electrochemical Detection (HPLC-EC).** To investigate concentrations of norepinephrine (NE) or epinephrine (Epi) in pre-SHR compared with Wistar stellates, whole fresh ganglia were dissected from 4-week pre-SHR (n=4 rats) and 4-week Wistar (n=8 rats). For each experiment, a single ganglion was cleaned, de-sheathed and allowed to recover in bicarbonate-buffered carbogenated Tyrode’s solution (5 min, 37 °C, 95 % O\(_2\) / 5 % CO\(_2\)). The ganglia were subsequently incubated in bicarbonate-
buffered Tyrode’s containing the NET-reuptake inhibitor, desipramine (1 μmol/L, 10 min, 37 °C). Ganglia were electrically stimulated (3 mA, 5 Hz, 5 min); parameters that were adapted from previous electrical stimulation methods. The perfusate was removed and perchloric acid (PCA, 0.1 mol/L) was added at each step to prevent the oxidation of catecholamines. Samples were kept on ice before freezing at -80 °C. At the end of each experiment, whole stellate ganglia were homogenized in bicarbonate-buffered Tyrode’s solution containing PCA (0.1 mol/L), centrifuged (15,000 G, 15 min, 4 °C) and the supernatant stored at -80 °C. For detection and quantification of NE and Epi, the samples were randomized, loaded into an autosampler (JASCO, Model AS-2055/2057) and detected with an isocratic HPLC system. HPLC separation was performed at the flow rate 1 mL / min using a C18 reverse-phase column (CP30710 Microsorb 100-5 C18 S250 x4.6mm, Agilent). The mobile phase (pH 4.7) comprised methanol (11.5% v/v), NaH₂PO₄ (120 mmol/L), EDTA (0.8 mmol/L), and sodium octane sulfonate (OSA, 0.5 mmol/L). Concentrations of NE and Epi were quantified using an LC-4B electrochemical detector and a carbon working electrode maintained at +0.7 V versus an Ag/AgCl reference electrode (Decade SDC, Antec). Chromatogram peaks were quantified (area under curve; CLARITY software) and the concentrations of NE were calculated against a 50 mg standard of NE and Epi dissolved in bicarbonate-buffered Tyrode’s containing PCA (0.1 mol/L). In the absence of any NA detection, cells were excluded from analysis.

**Statistical Analysis.** Data were analyzed using GraphPad Prism software (v6/7). When the data passed normality tests (D’Agostino-Pearson omnibus test or Shapiro-Wilk) unpaired two-tailed Student t-tests, or a one or two-way analysis of variance (ANOVA) were used. When the data were not normally distributed, the appropriate nonparametric tests were used with the specific statistical test reported in the figure legend. All data are expressed as the mean ± SEM. Statistical significance was accepted at p<0.05 unless otherwise described.
Supplementary References

1. Larsen HE, Bardsley EN, Lefkimmiatis K, Paterson DJ. Dysregulation of neuronal Ca\(^{2+}\) channel linked to heightened sympathetic phenotype in prohypertensive states. J Neurosci. 2016;36(33):8562-8573. doi:10.1523/JNEUROSCI.1059-16.2016.

2. Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, Szczéśniak MW, Gaffney DJ, Elo LL, Zhang X, Mortazavi A. A survey of best practices for RNA-seq data analysis. Genome Biol. 2016:1-19. doi:10.1186/s13059-016-0881-8.

3. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417-419. doi:10.1038/nmeth.4197.

4. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):31-62. doi:10.1186/s13059-014-0550-8.

5. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101-1108. doi:10.1038/nprot.2008.73.

6. Klarenbeek J, Goedhart J, van Batenburg A, Groenewald D, Jalink K. Fourth-generation Epac-based FRET sensors for cAMP feature exceptional brightness, photostability and dynamic range: characterization of dedicated sensors for FLIM, for ratiometry and with high affinity. Anderson KI, ed. PLoS ONE. 2015;10(4):1-11. doi:10.1371/journal.pone.0122513.

7. Depry C, Allen MD, Zhang J. Visualization of PKA activity in plasma membrane microdomains. Mol BioSyst. 2011;7(1):52-58. doi:10.1039/COMB00079E.

8. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca\(^{2+}\) indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260(6):3440-3450.

9. Buttgereit J, Shanks J, Li D, Hao G, Athwal A, Langenickel TH, Wright H, da Costa Goncalves AC, Monti J, Plehm R, Popova E, Qadri F, Lapidus I, Ryan B, Özcelik C, Paterson DJ, Bader M, Herring N. C-type natriuretic peptide and natriuretic peptide receptor B signalling inhibits cardiac sympathetic neurotransmission and autonomic function. Cardiovasc Res. 2016;112:637-644. doi:10.1093/cvr/cvw184.

10. Ghasemi A, Zahediasl S. Normality tests for statistical analysis: A guide for non-statisticians. Int J Endocrinol Metab. 2012;10(2):486-489. doi:10.5812/ijem.3505.
### Supplementary Results

#### Table S1

| Donor | Gender | Complications                                      |
|-------|--------|----------------------------------------------------|
| #19   | Male   | Non-ischemic cardiomyopathy, ventricular fibrillation, LVEF 30-35% |
| #23   | Male   | None noted                                         |
| #24   | Male   | None noted                                         |
Online Supplement: Neurotransmitter Switch in Prehypertension

Figure S1

A. Evoked-Ca\(^{2+}\): Rat

B. ICC Negative Controls

C. RNAseq Fold Change: Adult Rat

D. qRT-PCR Fold Change: Young and Adult Rat

E. qRT-PCR: Human

S1. There was no difference in sympathetic Ca\(^{2+}\) responses to 50 mmol/L between PGSNs obtained from 16-week Wistar or WKY rats. Given the absence of a Ca\(^{2+}\) phenotype, Wistar rats were used as the control in this study (A). For immunocytochemistry (ICC) experiments, the absence of staining with the primary antibody omitted was used as a control for nonspecific binding of the secondary antibody (B). The transcriptome of the sympathetic stellate ganglia was sequenced in 16-week old male Wistar rats (n=4) and age-matched SHR (n=4). Using RNAseq (C) and qRT-PCR (D) we identified the presence of β\(_1\)AR (Ardb1) and β\(_2\)AR (Ardb2) mRNA transcripts in addition to tyrosine hydroxylase (Th) and α\(_{2A}\)AR (Adra2a) mRNA transcripts. In the RNAseq dataset (C) Ardb2 expression was significantly lower in SHR ganglia compared with Wistar (p.adj = 0.00945; Salmon-DESeq2 method\(^4\)). Data points represent log\(_2\) (fold change) ± SEM. qRT-PCR validated the presence of transcripts in RNA extracted from 4-week (n=3/group) and 16-week rats (n=4/group). Fold changes were calculated by the ΔΔC\(_T\) method\(^5\), where the difference in counts between the gene of interest and the housekeeping gene (B2m) was calculated (Δ). The difference between the two strains (ΔΔ) was quantified and depicted as log\(_2\) (fold change) ± SEM. There was no significant difference in the levels of mRNA for Adrb1, Adrb2, Adra2a or Th between strains or between age groups (D). In stellate ganglia obtained from human donors (E), qRT-PCR confirmed mRNA transcripts encoding β\(_1\)AR (Adrb1) and β\(_2\)AR (Adrb2). Human stellate ganglia were also α\(_{2A}\)AR positive (Adra2a). qRT-PCR data were analyzed by the ΔC\(_T\) method\(^5\) where data represents the difference (Δ) in counts relative to the housekeeping gene B2m (E). Individual data points represent an average (of 3 technical replicates) from one human stellate (3 patients, 4 stellates, un-pooled samples).
Figure S2

A. EpacH187 FRET Sensor
Raw Fluorescence Example Trace: Rat

B. AKAR4 FRET Sensor
Raw Fluorescence Example Trace: Rat

C. Ca$^{2+}$ Imaging Time Controlled Experiment Example Trace: Rat

S2. Example YFP and CFP fluorescence traces over-time, as emitted from the cytosolic FRET sensors: EpacH187 (A) and AKAR4 (B) in response to ISO (10-100 nmol/L). Live Ca$^{2+}$ imaging was conducted on PGSNs obtained from 4-week control and pre-SHR PGSNs with Indo-1AM. A time-controlled raw fluorescence Ca$^{2+}$ trace is displayed (C). In time-controlled experiments, Wistar and pre-SHR PGSNs (n= 5, 6 respectively) were exposed to two KCl stimulations (50 mmol/L; S1, t = 0.25 mins; S2, t = 4 mins). There was no significant difference in Ca$^{2+}$ responses to high K$^+$ between strains, or between stimulation 1 and 2 independent of strain.
S3. Using RNAseq we identified the mRNA transcripts encoding enzymes required for norepinephrine (NE) synthesis: phenylalanine hydroxylase (Pah), Tyrosine Hydroxylase (Th), L-DOPA decarboxylase (Ddc), Dopamine β-hydroxylase (Dbh) and Phenylethanolamine-N-methyltransferase (Pnmt); the enzyme required for the conversion of NE to epinephrine (Epi). Pah and Ddc transcripts are significantly lower in SHR PGSNs (p.adj=0.0719 (Pah); 6.64 x 10^{-15} (Ddc); Salmon-DESeq2 method\textsuperscript{4}). mRNA transcripts are represented as Log\textsubscript{2}(Fold change) ± SEM (A). The presence of Pnmt and Th was confirmed by qRT-PCR in PGSNs from 4-week and 16-week Wistar and SHR. Data were normalized to B2m using the ∆∆C\textsubscript{T} method\textsuperscript{5} and expressed as Log\textsubscript{2}(Fold change) ± SEM (B). In human stellates, qRT-PCR confirmed the presence of Th and Pnmt (C). Data were normalized to a control housekeeping gene B2m using the ∆C\textsubscript{T} method\textsuperscript{5} where the data represents the difference (Δ) in counts relative to the housekeeping gene ± SEM (C). Individual data points represent an average (of 3 technical replicates) from one human stellate (3 patients, 4 stellates, un-pooled samples).